174 related articles for article (PubMed ID: 30003778)
1. Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
Löcken H; Clamor C; Müller K
J Nat Prod; 2018 Jul; 81(7):1636-1644. PubMed ID: 30003778
[TBL] [Abstract][Full Text] [Related]
2. A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3).
Li C; Chen C; An Q; Yang T; Sang Z; Yang Y; Ju Y; Tong A; Luo Y
Eur J Med Chem; 2019 Jan; 162():543-554. PubMed ID: 30472602
[TBL] [Abstract][Full Text] [Related]
3. STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with Proteasome Inhibition in Human Ovarian Cancer Cells.
Liu Y; Peng X; Li H; Jiao W; Peng X; Shao J; Xu Y; Wang R; Wang W; Kong D
Recent Pat Anticancer Drug Discov; 2021; 16(3):350-362. PubMed ID: 33655847
[TBL] [Abstract][Full Text] [Related]
4. Bioactivation of Napabucasin Triggers Reactive Oxygen Species-Mediated Cancer Cell Death.
Froeling FEM; Swamynathan MM; Deschênes A; Chio IIC; Brosnan E; Yao MA; Alagesan P; Lucito M; Li J; Chang AY; Trotman LC; Belleau P; Park Y; Rogoff HA; Watson JD; Tuveson DA
Clin Cancer Res; 2019 Dec; 25(23):7162-7174. PubMed ID: 31527169
[TBL] [Abstract][Full Text] [Related]
5. Identification of New Shikonin Derivatives as Antitumor Agents Targeting STAT3 SH2 Domain.
Qiu HY; Zhu X; Luo YL; Lin HY; Tang CY; Qi JL; Pang YJ; Yang RW; Lu GH; Wang XM; Yang YH
Sci Rep; 2017 Jun; 7(1):2863. PubMed ID: 28588262
[TBL] [Abstract][Full Text] [Related]
6. Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells.
Han D; Yu T; Dong N; Wang B; Sun F; Jiang D
J Exp Clin Cancer Res; 2019 Jul; 38(1):289. PubMed ID: 31277685
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative activities and SAR studies of substituted anthraquinones and 1,4-naphthoquinones.
Bhasin D; Etter JP; Chettiar SN; Mok M; Li PK
Bioorg Med Chem Lett; 2013 Dec; 23(24):6864-7. PubMed ID: 24176397
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
Thulin MH; Määttä J; Linder A; Sterbova S; Ohlsson C; Damber JE; Widmark A; Persson E
Prostate; 2021 Jun; 81(8):452-462. PubMed ID: 33822400
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of novel plumbagin derivatives as potent antitumor agents with STAT3 inhibition.
Li N; Ou J; Bao N; Chen C; Shi Z; Chen L; Sun J
Bioorg Chem; 2020 Nov; 104():104208. PubMed ID: 32919131
[TBL] [Abstract][Full Text] [Related]
10. Napabucasin, a novel inhibitor of STAT3, inhibits growth and synergises with doxorubicin in diffuse large B-cell lymphoma.
Li X; Wei Y; Wei X
Cancer Lett; 2020 Oct; 491():146-161. PubMed ID: 32798587
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and activity of BBI608 derivatives targeting on stem cells.
Zhou Q; Peng C; Du F; Zhou L; Shi Y; Du Y; Liu D; Sun W; Zhang M; Chen G
Eur J Med Chem; 2018 May; 151():39-50. PubMed ID: 29604543
[TBL] [Abstract][Full Text] [Related]
12. Identification of new shikonin derivatives as STAT3 inhibitors.
Qiu HY; Fu JY; Yang MK; Han HW; Wang PF; Zhang YH; Lin HY; Tang CY; Qi JL; Yang RW; Wang XM; Zhu HL; Yang YH
Biochem Pharmacol; 2017 Dec; 146():74-86. PubMed ID: 29066190
[TBL] [Abstract][Full Text] [Related]
13. The Anticancer Effect of Napabucasin (BBI608), a Natural Naphthoquinone.
Shao Z; Wang H; Ren H; Sun Y; Chen X
Molecules; 2023 Jul; 28(15):. PubMed ID: 37570646
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy.
Feng KR; Wang F; Shi XW; Tan YX; Zhao JY; Zhang JW; Li QH; Lin GQ; Gao D; Tian P
Eur J Med Chem; 2020 Sep; 201():112428. PubMed ID: 32603980
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of STAT3 blocks protein synthesis and tumor metastasis in osteosarcoma cells.
Zuo D; Shogren KL; Zang J; Jewison DE; Waletzki BE; Miller AL; Okuno SH; Cai Z; Yaszemski MJ; Maran A
J Exp Clin Cancer Res; 2018 Oct; 37(1):244. PubMed ID: 30286779
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Tumor Cell-Tumor Microenvironment Component Interactions as Potential Predictors of Patient Response to Napabucasin.
Chang AY; Hsu E; Patel J; Li Y; Zhang M; Iguchi H; Rogoff HA
Mol Cancer Res; 2019 Jul; 17(7):1429-1434. PubMed ID: 31043490
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and anticancer activity of some novel 5,6-fused hybrids of juglone based 1,4-naphthoquinones.
Mallavadhani UV; Prasad CV; Shrivastava S; Naidu VG
Eur J Med Chem; 2014 Aug; 83():84-91. PubMed ID: 24953027
[TBL] [Abstract][Full Text] [Related]
18. Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors.
Gao D; Jin N; Fu Y; Zhu Y; Wang Y; Wang T; Chen Y; Zhang M; Xiao Q; Huang M; Li Y
Eur J Med Chem; 2021 Apr; 216():113333. PubMed ID: 33689932
[TBL] [Abstract][Full Text] [Related]
19. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor.
Hubbard JM; Grothey A
Drugs; 2017 Jul; 77(10):1091-1103. PubMed ID: 28573435
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel STAT3 inhibitors bearing 2-acetyl-7-phenylamino benzofuran scaffold for antitumour study.
Wang F; Feng KR; Zhao JY; Zhang JW; Shi XW; Zhou J; Gao D; Lin GQ; Tian P
Bioorg Med Chem; 2020 Dec; 28(24):115822. PubMed ID: 33126089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
